Verona Pharma PLC American Depositary Share’s (VRNA) “Buy” Rating Reiterated at Wedbush

Wedbush restated their buy rating on shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) in a report released on Friday. Wedbush currently has a $33.00 target price on the stock.

Separately, Zacks Investment Research cut shares of Verona Pharma PLC American Depositary Share from a hold rating to a sell rating in a research report on Friday, November 10th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The company currently has an average rating of Buy and a consensus target price of $24.20.

Verona Pharma PLC American Depositary Share (VRNA) opened at $11.60 on Friday. Verona Pharma PLC American Depositary Share has a 1 year low of $10.44 and a 1 year high of $17.50.

A number of institutional investors have recently added to or reduced their stakes in VRNA. FIL Ltd acquired a new stake in Verona Pharma PLC American Depositary Share during the 2nd quarter worth approximately $873,000. Tekla Capital Management LLC acquired a new stake in Verona Pharma PLC American Depositary Share during the 2nd quarter worth approximately $3,211,000. Finally, Vivo Capital LLC acquired a new stake in Verona Pharma PLC American Depositary Share during the 2nd quarter worth approximately $8,208,000. Institutional investors own 40.27% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Verona Pharma PLC American Depositary Share’s (VRNA) “Buy” Rating Reiterated at Wedbush” was reported by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.truebluetribune.com/2017/12/12/verona-pharma-plc-american-depositary-shares-vrna-buy-rating-reiterated-at-wedbush.html.

About Verona Pharma PLC American Depositary Share

Verona Pharma plc, a clinical stage biopharmaceutical company, researches, discovers, and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. The company’s lead product is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which is in Phase IIa clinical trial that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, and asthma.

Receive News & Ratings for Verona Pharma PLC American Depositary Share Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma PLC American Depositary Share and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply